A phase III study of coversin in naive patients with paroxysmal nocturnal hemoglobinuria.

Trial Profile

A phase III study of coversin in naive patients with paroxysmal nocturnal hemoglobinuria.

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAPSTONE
  • Most Recent Events

    • 21 Sep 2017 According to an Akari Therapeutics media release, following advice from a recent FDA Type B End of Phase II Meeting, company plans to initiate this trial in Q1 2018.
    • 24 Apr 2017 According to Akari Therapeutics media release, the company is planning to initiate this phase III program in the fourth quarter of 2017 andanticipates initial data in first quarte of 2019.
    • 27 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top